文献速递泌尿男性生殖肿瘤

最耐药之路:转分化驱动前列腺癌对雄激素受体通路抑制的异常无反应

The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer.
PubMed 文献 · Cancer Discov · 2017-01-01

本文为Cancer Discovery同期评论,评述Zou等发现的细胞转分化机制可促进前列腺癌对抗雄激素治疗的异常耐药,Trp53与Pten共失活背景增加转分化神经内分泌表型频率,对抑制细胞可塑性、克服治疗耐药有启示。

要点

  • 转分化机制促进前列腺癌对抗雄激素治疗的异常耐药。
  • Trp53与Pten共失活背景增加转分化神经内分泌表型频率。
  • 该发现对开发抑制细胞可塑性、克服耐药的方法有启示。

核心结论

  • Zou等描述的细胞转分化机制促进前列腺癌对抗雄激素治疗的异常耐药。

研究设计与样本

  • 本文为Cancer Discovery同期评论,评述Zou等的研究。

主要发现

  • Trp53与Pten共失活背景增加转分化神经内分泌表型的频率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

<b/> In this issue of Cancer Discovery, Zou and colleagues describe a mechanism involving cellular transdifferentiation that promotes exceptional resistance to antiandrogen therapy in prostate cancer. A background of coinactivation of Trp53 and Pten increased the frequency of the transdifferentiated neuroendocrine phenotype. These findings have implications for developing approaches to repress cellular plasticity and overcome treatment resistance. Cancer Discov; 7(7); 673-4. ©2017 AACRSee related article by Zou et al., p. 736.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Sinha S, Nelson PS. The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer. Cancer Discov. 2017. PMID: 28684411. doi:10.1158/2159-8290.CD-17-0481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。